Tom Powles: Durvalumab with neoadjuvant chemo then cystectomy in MIBC

Tom Powles shared on X:

“Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS and OS versus chemo/cystectomy alone in muscle invasive bladder cancer.”

Source: Tom Powles/X

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.

With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.